SCHEMBL17199348

SCHEMBL17199348

O=C(Nc1nn(Cc2ccc(CF)cc2)c2ccccc12)c1ccsc1Cl

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FSCN1 Q16658 1/20 0.51
PTGER4 P35408 8/20 0.40
HDAC6 Q9UBN7 3/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC10 Q969S8 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
CNR1 P21554 1/20 0.38
CCR4 P51679 1/20 0.38
CPT1A P50416 2/20 0.37
CPT1B Q92523 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
KDM4C Q9H3R0 1/20 0.35
F2RL3 Q96RI0 1/20 0.35
MCL1 Q07820 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30695000 0.89 FSCN1 (0.66) FSCN1PTGER4HDAC6HDAC1HDAC10
SCHEMBL17038823 0.89 FSCN1 (0.66) FSCN1PTGER4HDAC6HDAC1HDAC10
SCHEMBL17199317 0.86 FSCN1 (0.51) FSCN1PTGER4HDAC6HDAC1HDAC10
SCHEMBL17199332 0.85 FSCN1 (0.54) FSCN1PTGER4HDAC6HDAC1HDAC10
SCHEMBL17199370 0.84 FSCN1 (0.51) FSCN1PTGER4HDAC6HDAC1HDAC10
SCHEMBL18937350 0.84 FSCN1 (0.51) FSCN1PTGER4HDAC6HDAC1HDAC10
SCHEMBL17199339 0.83 FSCN1 (0.55) FSCN1PTGER4CPT1A
SCHEMBL18532151 0.82 FSCN1 (0.53) FSCN1PTGER4HDAC6HDAC1HDAC10
SCHEMBL17199354 0.82 FSCN1 (0.53) FSCN1PTGER4HDAC6HDAC1HDAC10
SCHEMBL17199347 0.82 FSCN1 (0.60) FSCN1PTGER4HDAC6HDAC1HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9573946-B2 Compounds and methods for inhibiting fascin NOVITA PHARMACEUTICALS, INC. (US) 2017-02-21 US disclosed
US-20150299191-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN CORNELL UNIVERSITY 2015-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299191-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN FSCN1, MTPN, MYOF FSCN1 1/4885PTGER4 4107/4885HDAC6 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.